NOS3 and pulmonary arterial hypertension: Importantly, two recent clinical trials reported the safety and potential efficacy of endothelial progenitor cells overexpressing eNOS and autologous CD34 positive cell treatments in patients with pulmonary arterial hypertension and left ventricular dysfunction post-STEMI, respectively20,21.